Combining one of the world’s largest chemistry databases, Reaxys from Elsevier, with AI from Iktos, the platform will enable pharmaceutical companies to identify preclinical drug candidates faster, says Elsevier.
Elsevier, a global information and data analytics company, has announced it has signed a multi-year agreement with Iktos, a company specializing in artificial intelligence for new drug discovery. Elsevier says the partnership will strengthen its chemistry solution, Reaxys, by combining the company’s high-quality chemistry data with synthetic planning AI technologies developed by Iktos to accelerate chemistry research for pharmaceutical companies.
Mirit Eldor, managing director, Life Sciences Solutions, Elsevier said: “Our mission is to support research and development (R&D) organizations in fueling innovation and drug discovery with industry-leading predictive algorithms trained on our high-quality data. We are delighted to partner with Iktos to bring the valued industry insights that Reaxys offers powered by artificial intelligence, which will help reshape the landscape of small molecule discovery.”
The partnership aims to support R&D organizations to decrease the time required to complete Design-Make-Test-Analyze cycles of small molecules, thus reducing the length and cost of early-stage drug discovery. New predictive models will be launched to support use cases including retrosynthesis, synthetic accessibility, and other reaction-based analyses. The new tools will be delivered via Reaxys’ interface and Application Programming Interfaces (APIs), accelerating research for synthetic, medicinal, computational and process chemistry teams at pharmaceutical, agro-chemical and contract research organizations (CROs).
Yann Gaston-Mathé, CEO, Iktos said: “Data is the foundation of AI, and we are very excited to partner with Elsevier. We will combine the strength of Reaxys, a chemistry reaction database with unmatched volume, diversity, and quality, with Iktos' leading edge retrosynthesis AI technology. We are committed to making our technology available to R&D organizations around the world to maximize the impact of AI on the productivity of drug discovery.”
The new predictive retrosynthesis and synthetic accessibility tools are based on Iktos’ proprietary retrosynthetic technology and trained on Reaxys’ reaction database, added the publisher. The predictive retrosynthesis tools uses a template-based disconnection prediction model to apply a proprietary filter that scores reaction feasibility and includes chemo- and regioselectivity parameters. The solution space is explored using an advanced search functionality that delivers promising candidate routes in minutes. The new tools will offer multiple new features including stereochemistry support, defining first disconnection, ability to include or exclude intermediates, avoiding regioselectivity conflicts and defining price limit of starting materials. In addition, customers will have the option to customize the underlying model with proprietary reactions and libraries of starting materials, Elsevier continued.
The new predictive retrosynthesis and synthetic accessibility tools will be available as add-on modules for Reaxys customers. For more information, please click here.
Keep up-to-date with publishing news: sign up here for InPubWeekly, our free weekly e-newsletter.
